Status:

COMPLETED

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Lead Sponsor:

UNION therapeutics

Conditions:

Psoriasis

Skin Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis. The purpose of the study is to assess the ...

Eligibility Criteria

Inclusion

  • Capable of giving signed informed consent.
  • Male and female patients ≥18 years of age
  • Body weight of \>40 kg
  • Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable.
  • Moderate-to-severe plaque-type psoriasis as defined by Psoriasis Activity and Severity Index (PASI) ≥12, body surface area (BSA) ≥10%, and Investigator Global Assessment (IGA) ≥3.
  • Candidate for systemic antipsoriatic treatment or phototherapy.

Exclusion

  • Therapy-resistant psoriasis
  • Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit.
  • History of allergy or hypersensitivity to any component of the study treatment.
  • Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit.
  • Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.

Key Trial Info

Start Date :

December 30 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 20 2022

Estimated Enrollment :

202 Patients enrolled

Trial Details

Trial ID

NCT05190419

Start Date

December 30 2021

End Date

December 20 2022

Last Update

April 16 2024

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

Central Connecticut Dermatology

Cromwell, Connecticut, United States, 06416

2

GWU MFA

Washington D.C., District of Columbia, United States, 20037

3

ALLCUTIS Research, LLC

Beverly, Massachusetts, United States, 01915

4

ALLCUTIS Research, LLC

Portsmouth, New Hampshire, United States, 03801